[Thrombinogenesis in chronic myeloproliferative syndromes].
Haemostatic disturbances are important in clinical complications in patients with chronic myeloproliferative syndromes and sometimes the reason of death. Pathogenesis of thrombo-embolic disease during these states is not clear. The aim of study was the evaluation of the risk of thrombosis in patients with chronic myeloproliferative syndromes using very detailed test to measure the concentration of TAT (thrombin-antithrombin) complexes.


METHODS
The study was performed in 73 patients: in 22 with chronic myeloid leucaemia (CML), in 25 with polycythemia vera (PV), in 21 with essential thrombocytemia (ET) and in 5 with myelofibrosis (MF). The control group consisted of 29 healthy volunteers. In the blood plasma of studied persons concentration of TAT complexes and antithrombin (AT) activity were detected.


RESULTS
We observed in patients, except MF, significant increase of TAT but diminished AT activity.


CONCLUSIONS
Increased TAT complexes in chronic myeloproliferative syndromes is the evidence of significant thrombinogenesis. AT activity diminished in PV showes too high consumption of it with concomitant low synthesis.
Rość
Danuta
D
Uniwersytet Mikołaja Kpernika w Toruniu, Collegium Medicum w Bydgoszczy, Katedra Patofizjologii.
Kremplewska-Nalezyta
Elzbieta
E
Gadomska
Grazyna
G
Kowalewska
Anita
A
Buczkowska
Elzbieta
E
D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000188:drug therapy / Q000453:epidemiology*; D013922:Thrombocytosis / Q000188:drug therapy / Q000453:epidemiology*; D013927:Thrombosis / Q000188:drug therapy* / Q000453:epidemiology*
D005343:Fibrinolytic Agents